Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Imagem de Miniatura
Arquivos
art_FARIA_Genomics_and_epidemiology_of_the_P1_SARSCoV2_lineage_2021.PDF (281.36 KB)
Citações na Scopus
879
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER ASSOC ADVANCEMENT SCIENCE
Autores
FARIA, Nuno R.
MELLAN, Thomas A.
WHITTAKER, Charles
CANDIDO, Darlan da S.
MISHRA, Swapnil
CRISPIM, Myuki A. E.
HAWRYLUK, Iwona
MCCRONE, John T.
Citação
SCIENCE, v.372, n.6544, p.815-+, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Manaus, Brazil, resurged in late 2020 despite previously high levels of infection. Genome sequencing of viruses sampled in Manaus between November 2020 and January 2021 revealed the emergence and circulation of a novel SARS-CoV-2 variant of concern. Lineage P.1 acquired 17 mutations, including a trio in the spike protein (K417T, E484K, and N501Y) associated with increased binding to the human ACE2 (angiotensin-converting enzyme 2) receptor. Molecular clock analysis shows that P.1 emergence occurred around mid-November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.7- to 2.4-fold more transmissible and that previous (non-P.1) infection provides 54 to 79% of the protection against infection with P.1 that it provides against non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/41457
Referências
  1. Agencia Brasil, 2021, Covid-19: Amazonas ja transferiu 424 pacientes para outros estados.
  2. Aguiar, 2021, GENOMIC CHARACTERISA
  3. Alvarez-Antonio C., 2021, MEDRXIV21249913, DOI [10.1101/2021.01.17.21249913, DOI 10.1101/2021.01.17.21249913]
  4. Alvarez-Antonio C., 2021, SEROPREVALENCE ANTIS, DOI [10.1101/2021.01.17.21249913, DOI 10.1101/2021.01.17.21249913]
  5. [Anonymous], GITHUB REPOSITORY
  6. [Anonymous], 2021, SAMRC REPORT WEEKLY
  7. Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049
  8. Ayres DL, 2012, SYST BIOL, V61, P170, DOI 10.1093/sysbio/syr100
  9. BELLMAN R, 1952, ANN MATH, V55, P280, DOI 10.2307/1969779
  10. Bletsa M, 2019, VIRUS EVOL, V5, DOI 10.1093/ve/vez036
  11. Borremans B, 2020, ELIFE, V9, DOI 10.7554/eLife.60122
  12. Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5
  13. Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
  14. Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
  15. Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5
  16. SAMRC, 2021, REP WEEKL DEATHS S A
  17. Paiva MHS, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121414
  18. Schrodinger L, 2015, PYMOL MOL GRAPHICS V
  19. Scott James, BAYESIAN MODELS
  20. Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
  21. Siqueira J. D., 2020, SARS COV 2 GENOMIC Q
  22. Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
  23. SPHERES, 2020, SARS COV 2 SEQ PUBL
  24. SRAG, 2020, BANC DAD SINDR RESP
  25. Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012
  26. Stephen K, 2021, SARS COV 2
  27. Suchard MA, 2003, SYST BIOL, V52, P48, DOI 10.1080/10635150390132713
  28. Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
  29. Tegally H, 2021, NATURE, DOI 10.1038/s41586-021-03402-9
  30. TESSy, 2015, EUROPEAN SURVEILLANC
  31. The R Core Team, 2013, R LANG ENV STAT COMP
  32. Tyson J. R, 2020, BIORXIV2020090428307
  33. Unwin HJT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19652-6
  34. Viana G.M.R., MOL EPIDEMIOLOGY UND, DOI [10.1101/2020.09.04.20184523, DOI 10.1101/2020.09.04.20184523]
  35. Voloch CM, 2021, J VIROL, V95, DOI 10.1128/JVI.00119-21
  36. Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x
  37. Volz E, 2021, CELL, V184, P64, DOI 10.1016/j.cell.2020.11.020
  38. Wang ZJ, 2021, NATURE, V592, P616, DOI [10.1038/s41586-021-03324-6, 10.1080/14786419.2021.1960326]
  39. Wang Zijun, 2021, bioRxiv, DOI 10.1101/2021.01.15.426911
  40. Washington Nicole L, 2021, medRxiv, DOI 10.1101/2021.02.06.21251159
  41. Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312
  42. Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759
  43. Wibmer CK, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01285-x
  44. World Health Organization, 2021, GEN SEQ SARS COV 2 G GEN SEQ SARS COV 2 G
  45. Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
  46. Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7
  47. Xavier J, 2020, EMERG MICROBES INFEC, V9, P1824, DOI 10.1080/22221751.2020.1803146
  48. Xu B, 2020, LANCET INFECT DIS, V20, P534, DOI 10.1016/S1473-3099(20)30119-5
  49. YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154
  50. Zhou D., 2021, CELL
  51. Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037
  52. Buss LF, 2021, SCIENCE, V371, P288, DOI 10.1126/science.abe9728
  53. CADDE CENTRE S., 2021, Zenodo, DOI 10.5281/zenodo.4676853zenodo.4676853
  54. CADDE CENTRE S., 2021, Zenodo, DOI 10.5281/zenodo.4676853
  55. Candido DD, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa042
  56. Candido DS, 2020, SCIENCE, V369, P1255, DOI 10.1126/science.abd2161
  57. Cele S, 2021, NATURE, V593, P142, DOI 10.1038/s41586-021-03471-w
  58. Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364
  59. Claro IM, 2021, EMERG INFECT DIS, V27, P970, DOI 10.3201/eid2703.210038
  60. COG-UK, 2020, COVID 19 GEN UK CONS
  61. de Jesus JG, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062030, 10.1590/s1678-9946202062030]
  62. de Souza WM, 2020, NAT HUM BEHAV, V4, P856, DOI 10.1038/s41562-020-0928-4
  63. Drummond AJ, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-114
  64. du Plessis L, 2021, SCIENCE, V371, P708, DOI 10.1126/science.abf2946
  65. Farfour E, 2020, EUR J CLIN MICROBIOL, V39, P1997, DOI 10.1007/s10096-020-03930-8
  66. Faria N. R., 2021, BEHALF CADDE GENOMIC
  67. Feller W, 1941, ANN MATH STAT, V12, P243, DOI 10.1214/aoms/1177731708
  68. Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
  69. Franceschi VB., 2021, GENOMIC EPIDEMIOLOGY, DOI [10.1101/2021.01.21.21249906, DOI 10.1101/2021.01.21.21249906]
  70. Fujino T, 2021, EMERG INFECT DIS, V27, P1243, DOI 10.3201/eid2704.210138
  71. Fundacao de Vigilancia em Saude do Amazonas, 2021, PERFIL CLIN DEMOGGRA
  72. Fundacao de Vigilancia em Saude do Amazonas Amazonas, 2021, DAD EP FIN AC COMB C
  73. Gill MS, 2013, MOL BIOL EVOL, V30, P713, DOI 10.1093/molbev/mss265
  74. Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003
  75. Hall v, 2021, ANTIBODY POSITIVE HE, DOI [10.1101/2021.01.13.21249642, DOI 10.1101/2021.01.13.21249642]
  76. Hall V., 2021, BIORXIV21249642, DOI [10.1101/2021.01.13.21249642, DOI 10.1101/2021.01.13.21249642]
  77. Hallal PC, 2020, LANCET GLOB HEALTH, V8, pE1390, DOI 10.1016/S2214-109X(20)30387-9
  78. Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4
  79. HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
  80. Hawryluk I, 2021, ARXIV210211249
  81. Hawryluk I, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2020.0596
  82. Hay James A, 2021, medRxiv, DOI 10.1101/2020.10.08.20204222
  83. Hellewell J., 2020, ESTIMATING EFFECTIVE, DOI [10.1101/2020.11.24.20229948, DOI 10.1101/2020.11.24.20229948]
  84. Francisco RD, 2021, VIRUS RES, V296, DOI 10.1016/j.virusres.2021.198345
  85. Jukes T. H., 1969, MAMMALIAN PROTEIN ME, P21, DOI [DOI 10.1016/B978-1-4832-3211-9.50009-7, DOI 10.1093/BIOINFORMATICS/BTM404]
  86. Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
  87. Kidd M., 2021, J INFECT DIS JIAB082, DOI [10.1093/infdis/jiab082 Medline, DOI 10.1093/INFDIS/JIAB082MEDLINE]
  88. Kidd M., 2021, J INFECT DIS
  89. Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
  90. Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
  91. Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
  92. Liotti FM, 2021, EUR J CLIN MICROBIOL, V40, P269, DOI 10.1007/s10096-020-04025-0
  93. MacLean O. A., 2020, EV SIGNIFICANT NATUR
  94. Marks M., 2021, LANCET INFECT DIS, V20, pS1473, DOI [10.1016/S1473-3099(20)30985-3 Medline, DOI 10.1016/S1473-3099(20)30985-3MEDLINE]
  95. Marks M., 2021, LANCET INFECT DIS S, pS1473
  96. Martins A. F, 2021, Euro Surveill., V26, DOI 10.2807/1560-7917.ES.2021.26.12.2100276
  97. McGough SF, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007735
  98. Mellan T., 2020, REPORT 21 ESTIMATING, DOI [10.25561/78872, DOI 10.25561/78872]
  99. Mercado M., 2020, Seroprevalencia de SARSCoV- 2 durante la epidemia en Colombia: estudio pais
  100. Milne I, 2010, BIOINFORMATICS, V26, P401, DOI 10.1093/bioinformatics/btp666
  101. Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015
  102. Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764
  103. Nascimento LV, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760190347
  104. Naveca F, COVID 19 EPIDEMIC BR, P2021, DOI [10.21203/rs.3.rs-275494/v1, DOI 10.21203/RS.3.RS-275494/V1]
  105. O'Toole A, 2021, TRACKING INT SPREAD
  106. Peixoto PS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235732
  107. Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037
  108. Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
  109. Qu XX, 2005, J BIOL CHEM, V280, P29588, DOI 10.1074/jbc.M500662200
  110. Rambaut A., 2020, VIROLOGICAL

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - ODS/03